Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach

  title={Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach},
  author={Ga{\"e}l Qesseveur and Anne-C{\'e}cile Petit and Hai Thanh Nguyen and Lionel Dahan and Romain Colle and Samuel Rotenberg and Isabelle Seif and Pauline Robert and Denis J David and Jean-Philippe Guilloux and Alain M. Gardier and C{\'e}line Verstuyft and Laurent Becquemont and Emmanuelle Corruble and Bruno P. Guiard},

Figures and Tables from this paper

Gene-Based Association Analysis Suggests Association of HTR2A With Antidepressant Treatment Response in Depressed Patients

This current investigation supported the link between HTR2A variants and antidepressant therapeutic response in MDD but not with MDD susceptibility, and identified 14 polymorphisms as suggestive markers for therapeutic responded in both meta- and mega-analyses.

Pharmacogenetics of Major Depressive Disorder (MDD): Progress in Two Serotonergic Targets

The results indicate that while there is significant potential for predicting treatment response associated with two 5-HT related genes: SLC6A4 and HTR2A, there is much work left to be done to establish conclusive evidence for and feasibility of pharmacogenetic testing.

Role of Serotonin-2A Receptors in Pathophysiology and Treatment of Depression

This chapter aims to summarize the up-to-day evidence-based biomedical knowledge on serotonin-2A (5-HT2A) receptors and their role in pathophysiology and treatment of central nervous system (CNS)

Highlights on Pharmacogenetics and Pharmacogenomics in Depression

This chapter summarizes the current knowledge about the pharmacogenetics and pharmacogenomics of antidepressant drugs in major depressive disorder and analysis approaches derived from GWAS are expected to provide better power to identify the complex polygenic profile modulating antidepressant response.

Pharmacogenetics and Imaging–Pharmacogenetics of Antidepressant Response: Towards Translational Strategies

There is mounting evidence that genetic factors exert their impact on treatment response by influencing brain structural and functional changes during antidepressant treatment, and combining neuroimaging and genetic methods may be a more powerful way to detect biological mechanisms of response than either method alone.

The association of β-arrestin2 polymorphisms with response to antidepressant treatment in depressed patients

Genetic variants in major depressive disorder: From pathophysiology to therapy

Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample

This study investigated the role of a set of genes involved in different pathways in the treatment outcome of major depressive disorder (MDD) and bipolar disorder (BD) after naturalistic pharmacological treatment to support the involvement of some candidate genes in the outcomes of treatments for mood disorders, as well as in BD risk and other disease features.

The ERICH3 rs11580409 polymorphism is associated with 6-month antidepressant response in depressed patients



Converging translational evidence for the involvement of the serotonin 2A receptor gene in major depressive disorder

Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy

It is suggested that genetically determined variation in serotonin receptor genes makes a significant contribution to the efficacy of commonly prescribed antidepressant drugs.

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.

There is a compelling case for a key role of HTR2A in the mechanism of antidepressant action, as detected in patients treated with the antidepressant citalopram.

5-HT2A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system

The blockade of the 5-HT2AR may strengthen the antidepressant-like effect of escitalopram by facilitating the enhancement of the brain NE transmission and provide support for the use of atypical antipsychotics with SSRIs as a relevant antidepressant augmentation strategy.

Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.

There are many inconsistencies, particularly between candidate gene and genome-wide association studies, but some consistency is seen in candidate gene studies supporting established pharmacological mechanisms of antipsychotic and antidepressant response with associations of functional genetic polymorphisms in the dopamine D2 receptor and serotonin transporter and receptors.

HTR2A is Associated with SSRI Response in Major Depressive Disorder in a Japanese Cohort

It is suggested that HTR2A may play an important role in the pathophysiology of the therapeutic response to SSRIs in Japanese MDD patients, and it will be important to replicate and confirm these findings in other independent studies using large samples.

Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder

The finding suggests that 5-HTTLPR, STin2, H TR1A, HTR2A, TPH1 and BDNF may modulate antidepressant response.

No Effect of Serotoninergic Gene Variants on Response to Interpersonal Counseling and Antidepressants in Major Depression

This study confirms that IPC is an effective psychological intervention comparable to antidepressants in mild-moderate MDD and Polymorphisms related to the serotonin system did not exert a major effect on clinical outcomes in none of the treatment groups.